BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management

Completed · Phase 3 · Has a placebo group

Conditions studied: Obesity

In brief

The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients.

Key facts

Study ID

NCT00603902

Run by

Eisai Inc.

People needed

4008

Starts

2008-01-01

Expected to finish

2009-08-01

Last updated by the study team

2019-10-04

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Overweight and/or obese men and women with a body mass index (BMI) 30 to 45 kg/m2 with or without a comorbid condition (e.g., hypertension, dyslipidemia, CV disease, glucose intolerance, sleep apnea), or 27 to 29.9 kg/m2 with at least one comorbid condition.
• Ability to complete a 1 year study

You may not qualify if…

• Pregnancy
• Diabetes mellitus (type I, II or other)
• History of symptomatic heart valve disease
• Serious or unstable current or past medical conditions

Where it is running

• Arena Pharmaceuticals, Inc. — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.